Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: A new in vivo model

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 1, 2004, Pages 125-135

  Haugan, Ketil ^a   Lam, Henrik Rye ^b   Knudsen, Carsten Boye ^a   Petersen, Jørgen Søberg ^a  

^a Zealand Pharma AS   (Denmark)

^b Inst of Food Safety and Toxicology   (Denmark)

Author keywords

Antiarrhythmic agents; Autonomic nervous system; Gap junctions; Hemodynamics; Supraventricular arrhythmia

Indexed keywords

ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC PEPTIDE 10; CATECHOLAMINE; FLECAINIDE; NORADRENALIN; PEPTIDE DERIVATIVE; PROPRANOLOL; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; ASPHYXIA; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD GAS ANALYSIS; BLOOD PRESSURE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; ELECTROCARDIOGRAM; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ASPHYXIA; ATRIAL FIBRILLATION; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GAP JUNCTIONS; HEART RATE; MALE; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3042818988     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200407000-00017     Document Type: Article

References (46)

1. Friedrichs GS. Experimental models of atrial fibrillation/flutter. J Pharmacol Toxicol Methods. 2000;43:117-123.
2. Wang J, Bourne GW, Wang Z, et al. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation. 1993;88:1030-1044.
3. Geddes LA, Hinds M, Babbs CF, et al. Maintenance of atrial fibrillation in anesthetized and unanesthetized sheep using cholinergic drive. Pacing Clin Electrophysiol. 1996;19:165-175.
4. Wakimoto H, Maguire CT, Kovoor P, et al. Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res. 2001;50:463-473.
5. Hagendorff A, Schumacher B, Kirchhoff S, et al. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation. 1999;99:1508-1515.
6. Lammers WJ, Kirchhof C, Bonke FI, et al. Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol. 1992;262:H47-H55.
7. Dimmer C, Tavemier R, Gjorgov N, et al. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1998;82:22-25.
8. Coccagna G, Capucci A, Bauleo S, et al. Paroxysmal atrial fibrillation in sleep. Sleep. 1997;20:396-398.
9. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002;105:2753-2759.
10. Muller A, Schaefer T, Linke W, et al. Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:76-82.
11. Grover R, Dhein S. Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration. Peptides. 2001;22:1011-1021.
12. Kjølbye AL, Knudsen CB, Jepsen T, et al. Pharmacological characterization of the new stable antiarrhythmic peptide analogue ZP123: In vivo and in vitro studies. Journal of Pharmacology & Experimental Therapeutics. 2003;306:1191-1199.
13. Diker E, Ozdemir M, Aydogdu S, et al. Dispersion of repolarization in paroxysmal atrial fibrillation. Int J Cardiol. 1998;63:281-286.
14. Li Z, Hertervig E, Carlson J, et al. Dispersion of refractoriness in patients with paroxysmal atrial fibrillation. Evaluation with simultaneous endocardial recordings from both atria. J Electrocardiol. 2002;35:227-234.
15. Anton AH, Sayre DF. A study of the factors affecting the aluminum oxidetrihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther. 1962;138:360-375.
16. Schrickel JW, Bielik H, Yang A, et al. Induction of atrial fibrillation in mice by rapid transesophageal atrial pacing. Basic Res Cardiol. 2002;97: 452-460.
17. Platou ES, Refsum H. Class III antiarrhythmic action in experimental atrial fibrillation and flutter in dogs. J Cardiovasc Pharmacol. 1982;4: 839-846.
18. Wijffels MC, Dorland R, Allessie MA. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol. J Cardiovasc Electrophysiol. 1999;10:178-193.
19. Gautam CS, Lal R, Pandhi P, et al. Differential effect of some antiarrhythmic drugs in right- or left- sided aconitine-induced experimental atrial arrhythmias. Meth Find Exp Clin Pharmacol. 1987;9:91-93.
20. Wang Z, Page P, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 1992;71:271-287.
21. Allessie MA, Wijffels MC, Dorland R. Mechanisms of pharmacologic cardioversion of atrial fibrillation by Class I drugs. J Cardiovasc Electrophysiol. 1998;9:S69-S77.
22. Naccarelli GV, Hynes J, Wolbrette DL, et al. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation. Curr Cardiol Rep. 2002;4:418-425.
23. Shenasa M, Kus T, Fromer M, et al. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol. 1988;62:403-407.
24. Benardeau A, Fareh S, Nattel S. Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. Cardiovasc Res. 2001; 50:85-96.
25. Duytschaever MF, Garratt CJ, Allessie MA. Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. J Cardiovasc Electrophysiol. 2000;11:1375-1385.
26. Hirose M, Carlson MD, Laurita KR. Cellular mechanisms of vagally mediated atrial tachyarrhythmia in isolated arterially perfused canine right atria. J Cardiovasc Electrophysiol. 2002;13:918-926.
27. Fukuda Y, Sato A, Suzuki A, et al. Autonomic nerve and cardiovascular responses to changing blood oxygen and carbon dioxide levels in the rat. J Auton Nerv Syst. 1989;28:61-74.
28. Scherlag BJ, Yamanashi WS, Schauerte P, et al. Endovascular stimulation within the left pulmonary artery to induce slowing of heart rate and paroxysmal atrial fibrillation. Cardiovasc Res. 2002;54:470-475.
29. Famebo LO, Hallman H, Hamberger B, et al. Catecholamines and hemorrhagic shock in awake and anesthetized rats. Circ Shock. 1979;6:109-118.
30. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 1996;7:999-1007.
31. Esler M, Jennings G, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3-20.
32. Cryer P. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med. 1980;303:436-444.
33. Stephenson LW, MacVaugh H III, Tomasello DN, et al. Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study. Ann Thorac Surg. 1980;29:113-116.
34. Kjølbye AL, Holstein-Rathlou NH, Petersen JS. Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts. J Cardiovasc Pharmacol. 2002;40:770-779.
35. Kneller J, Zou R, Vigmond EJ, et al. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res. 2002;90:E73-E87.
36. Hayashi H, Wang C, Miyauchi Y, et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2002; 13:801-808.
37. Ohara T, Qu Z, Lee MH, et al. Increased vulnerability to inducible atrial fibrillation caused by partial cellular uncoupling with heptanal. Am J Physiol Heart Circ Physiol. 2002;283:H1116-H1122.
38. Dhein S, Manicone N, Muller A, et al. A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:174-184.
39. Xing D, Kjølbye AL, Nielsen MS, et al. ZP123 Increases Gap Junctional Conductance and Prevents Reentrant Ventricular Tachycardia During Myocardial Ischemia in Open Chest Dogs. J Cardiovasc Electrophysiol. 2003;14:510-520.
40. Kohama Y, Kuwahara S, Yamamoto K, et al. Effect of N-3-(4-hydroxyphenyl) propionyl Pro-Pro-Gly-Ala-Gly on calcium-induced arrhythmias. Chem Pharm Bull (Tokyo). 1988;36:4597-4599.
41. Ronsberg MA, Saunders TK, Chan PS, et al. The antiarrhythmic effect of antiarrhythmic peptide (Gly-Pro-4Hyp-Gly-Ala-Gly) and its analog on chemically-induced arrhythmias in mice. Med Sci. 86 A.D.;14:350-351.
42. Beardslee MA, Lerner DL, Tadros PN, et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res. 2000;87:656-662.
43. Tabata T, Grimm RA, Greenberg NL, et al. Assessment of LV systolic function in atrial fibrillation using an index of preceding cardiac cycles. Am J Physiol Heart Circ Physiol. 2001;281:H573-H580.
44. Tarka EA, Blitz LR, Herrmann HC. Hemodynamic effects and long-term outcome of percutaneous balloon valvuloplasty in patients with mitral stenosis and atrial fibrillation. Clin Cardiol. 2000;23:673-677.
45. Orlando JR, van Herick R, Aronow WS, et al. Hemodynamics and echocardiograms before and after cardioversion of atrial fibrillation to normal sinus rhythm. Chest. 1979;76:521-526.
46. Barrett TD, Hayes ES, Yong SL, et al. Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats. Eur J Pharmacol. 2000;398:365-374.